跳至主要内容
临床试验/NCT05291650
NCT05291650已完成4 期

Ultrasound-guided Injection of Glucocorticoid Into Infrapatellar Fat Pad Versus Placebo Injection in Knee Osteoarthritis: a 12-week Double-blinded Controlled Trial

Zhujiang Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年4月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
the change of effusion-synovitis volume

研究概览

简要总结

This aims of this study is to investigate the efficacy and safety of the glucocorticoid injection into the infrapatellar fat pad among knee osteoarthritis patients with an inflammatory phenotype.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with symptomatic knee osteoarthritis (OA) according to American College of Rheumatology criteria;
  • Age > 45 years;
  • Have knee pain for more than six months and the knee pain over the past week assessed by VAS (100 mm) ≥ 40 mm;
  • Ultrasonography showed obvious synovitis with effusion in the knee joint;
  • Both MRI-assessed Hoffa-synovitis score (MOAKS method) and effusion-synovitis score (modified WORMS method) ≥ 1, and their total score ≥ 3;
  • Being able to listen, speak, read and understand Chinese, capable of understanding the study requirements and cooperating with the researchers during the study, and providing written informed consent.

排除标准

  • Allergy to glucocorticoids;
  • Knee injection of glucocorticoid or hyaluronic acid within the past six months;
  • Severe trauma or arthroscopy in the knee within the past six months;
  • Planned hip or knee surgery (including arthroscopy, arthroplasty, and other open joint surgeries) in the next six months;
  • Contraindication to having magnetic resonance imaging (MRI) (e.g., implanted pacemaker, artificial metal valve or cornea, aneurysm clipping surgery, arterial dissection, metal foreign bodies in the eyeball, claustrophobia);
  • Presence of other arthritis, such as rheumatoid arthritis and psoriatic arthritis;
  • Other physical condition that is more painful than their knee OA;
  • Malignant tumors or other life-threatening diseases;
  • Infection, diabetes, coagulopathy, osteonecrosis, or gastric/duodenal ulcer within the past 12 months;
  • Current use of oral corticosteroids, nonsteroidal anti-inflammatory drugs, or immunosuppressive medication;
  • Pregnancy or lactating female;
  • Use any investigational drugs or devices in the recent 30 days.

研究组 & 干预措施

glucocorticoid injection into infrapatellar fat pad

Active Comparator

干预措施: Glucocorticoids (Drug)

glucocorticoid injection into infrapatellar fat pad

Active Comparator

干预措施: Hyaluronic acid (Drug)

placebo injection into infrapatellar fat pad

Placebo Comparator

干预措施: Saline (Drug)

placebo injection into infrapatellar fat pad

Placebo Comparator

干预措施: Hyaluronic acid (Drug)

结局指标

主要结局

the change of effusion-synovitis volume

时间窗: over 12 weeks (assessed at baseline and the 12th week)

the change of magnetic resonance imaging assessed effusion-synovitis volume

the knee pain change

时间窗: over 12 weeks (assessed at baseline, the 4th week, the 8th week, and the 12th week)

the knee pain change measured with visual analogue scale (VAS, 0-100), a higher VAS score means more severe pain

次要结局

  • the change in WOMAC score(over 12 weeks (assessed at baseline, the 4th week, the 8th week, and the 12th week))
  • the change in Hoffa-synovitis score(over 12 weeks (assessed at baseline and the 12th week))
  • the change in quality of life(over 12 weeks (assessed at baseline, the 4th week, the 8th week, and the 12th week))
  • the change in pain medication use(over 12 weeks (assessed at baseline, the 4th week, the 8th week, and the 12th week))
  • the change in Infrapatellar fat pad volume(over 12 weeks (assessed at baseline and the 12th week))
  • adverse reaction(the 4th week, the 8th week, and the 12th week)

研究者

发起方
Zhujiang Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验